We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

79 hedge funds and large institutions have $58.2M invested in Aclaris Therapeutics in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 26 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,100% more call options, than puts

Call options by funds: $112K | Put options by funds: $1K

85% more capital invested

Capital invested by funds: $31.4M → $58.2M (+$26.8M)

4.16% more ownership

Funds ownership: 70.29% → 74.45% (+4.2%)

8% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 26

2% less funds holding

Funds holding: 81 → 79 (-2)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

Holders
79
Holders Change
-2
Holders Change %
-2.47%
% of All Funds
1.56%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
24
Reduced
26
Closed
12
Calls
$112K
Puts
$1K
Net Calls
+$111K
Net Calls Change
+$156K

Top Buyers

Rank Fund Capital Flow
1
MP
MFN Partners
Massachusetts
+$4.14M
2
EC
EcoR1 Capital
California
+$3.46M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.35M
4
Morgan Stanley
Morgan Stanley
New York
+$1.31M
5
ECM
Endurant Capital Management
California
+$473K

Top Sellers

Rank Fund Capital Flow
1
Man Group
Man Group
United Kingdom
-$4.04M
2
RSCM
Rock Springs Capital Management
Maryland
-$2.28M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.05M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$884K
5
BlackRock
BlackRock
New York
-$650K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$210K +$184K +111,166 New
N
27
Nuveen
North Carolina
$191K -$23.7K -14,287 -12%
BCM
28
Bridgeway Capital Management
Texas
$165K – – –
Charles Schwab
29
Charles Schwab
California
$161K – – –
Barclays
30
Barclays
United Kingdom
$159K +$111K +66,735 +390%
Squarepoint
31
Squarepoint
New York
$159K +$139K +83,924 New
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$132K -$1.05M -631,696 -90%
HighTower Advisors
33
HighTower Advisors
Illinois
$113K – – –
Tudor Investment Corp
34
Tudor Investment Corp
Connecticut
$111K – – –
Two Sigma Advisers
35
Two Sigma Advisers
New York
$109K -$161K -97,100 -63%
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$106K +$3.21K +1,935 +4%
AllianceBernstein
37
AllianceBernstein
Tennessee
$104K – – –
HF
38
HRT Financial
New York
$93K +$81.7K +49,323 New
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$88K -$1.08K -653 -1%
Goldman Sachs
40
Goldman Sachs
New York
$86K +$6.24K +3,767 +9%
Cambridge Investment Research Advisors
41
Cambridge Investment Research Advisors
Iowa
$84K – – –
VF
42
Virtu Financial
New York
$73K -$25.6K -15,471 -29%
Deutsche Bank
43
Deutsche Bank
Germany
$73K +$50.3K +30,372 +327%
UBS Group
44
UBS Group
Switzerland
$71K +$47.6K +28,749 +317%
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$58K +$3.58K +2,157 +8%
Creative Planning
46
Creative Planning
Kansas
$57K – – –
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$56K – – –
OAM
48
Oxford Asset Management
United Kingdom
$52K +$45.7K +27,599 New
Citadel Advisors
49
Citadel Advisors
Florida
$51K -$79.5K -47,963 -64%
Invesco
50
Invesco
Georgia
$51K -$2.99K -1,805 -6%
1
2
3 4

ACRS Hedge Fund Activity: Q4 2019 in Review

79 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2019, worth a combined $58.2M — up 85% from $31.4M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of ACRS and 10 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 24 added.

The largest buyer was MFN Partners, adding an estimated $4.14M. The largest seller was Man Group, cutting an estimated $4.04M.

  • 79 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2019, down from 81 in Q3 2019.
  • Funds reported $58.2M of Aclaris Therapeutics stock for Q4 2019, up 85% quarter-over-quarter.
  • 10 funds opened new Aclaris Therapeutics positions in Q4 2019 and 12 closed out, a net change of -2 holders.
  • The largest Aclaris Therapeutics buyer in Q4 2019 was MFN Partners, an estimated $4.14M added.
  • The largest Aclaris Therapeutics seller in Q4 2019 was Man Group, an estimated $4.04M sold.

Based on aggregated 13F filings for Q4 2019.